Stratos Wealth Partners LTD. Has $6.66 Million Position in Pfizer Inc. (NYSE:PFE)

Stratos Wealth Partners LTD. decreased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.7% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 262,752 shares of the biopharmaceutical company's stock after selling 18,774 shares during the period. Stratos Wealth Partners LTD.'s holdings in Pfizer were worth $6,658,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Providence Capital Advisors LLC increased its stake in shares of Pfizer by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock valued at $3,034,000 after buying an additional 409 shares in the last quarter. Donaldson Capital Management LLC lifted its stake in Pfizer by 1.2% in the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock valued at $947,000 after acquiring an additional 410 shares in the last quarter. William B. Walkup & Associates Inc. increased its position in shares of Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after acquiring an additional 454 shares during the last quarter. Sutton Place Investors LLC raised its position in Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after acquiring an additional 472 shares in the last quarter. Finally, Balboa Wealth Partners lifted its position in shares of Pfizer by 1.6% in the fourth quarter. Balboa Wealth Partners now owns 30,678 shares of the biopharmaceutical company's stock valued at $814,000 after buying an additional 480 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. The Goldman Sachs Group boosted their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Leerink Partners lowered their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. Redburn Atlantic decreased their price target on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald assumed coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Price Performance

Shares of PFE opened at $25.61 on Wednesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The stock has a market cap of $145.60 billion, a P/E ratio of 18.56, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The stock's 50-day moving average price is $23.80 and its two-hundred day moving average price is $24.81.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.82 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.72%. Pfizer's payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.